Dr. Fang Jianmin, served as a director of the company from October 2008 to April 2020, and has served as the company’s executive director since May 2020. He is mainly responsible for the company’s overall management, business and strategic planning, and is fully responsible for the company’s drug research and development.

Dr. Fang Jianmin has been engaged in the research and development of novel drugs for more than 20 years, possessing experience in leading multiple innovative biopharmaceuticals from early discovery to commercialization, and holding over 50 drug-related invention patents. He obtained his PhD in Biology from Dalhousie University in Canada in May 1998, and served as a postdoctoral fellow at Harvard Medical School's Department of Surgery/Boston Children's Hospital from 1997 to 2000.

Dr. Fang served as a member of overall expert group for the national significant science and technology project “Significant New Drug Creation” during the “Twelfth Five-Year Plan” and the “Thirteenth-Five-Year Plan” period. He was awarded the “National Distinguished Expert” , the “Taishan Scholar” of Shandong Province, and the “Qilu Outstanding Talent Award” etc. Currently, he is a professor and doctoral supervisor at the School of Life Sciences and Technology, Tong Ji University.